Alarcón-Sotelo A, Gómez-Romero P, De Regules-Silva S, Pardinas-Llergo MJ, Rodríguez-Weber FL, Díaz-Greene EJ

Idioma: Español
Referencias bibliográficas: 59
Paginas: 946-958
Archivo PDF: 428.73 Kb.

RESUMEN

La obesidad es una enfermedad crónica, con afección sistémica y de carácter multifactorial que constituye un grave problema de salud pública, considerada por la Organización Mundial de la Salud una epidemia global. La obesidad es resultado del equilibrio energético positivo por tiempo prolongado, donde la energía derivada de los alimentos excede la energía gastada en la vida cotidiana. En vía de poner fin a este problema de salud pública se han buscado opciones de tratamiento, si bien las modificaciones al estilo de vida, incluida la dieta y el ejercicio, siguen siendo la piedra angular del tratamiento de la obesidad, estas modificaciones no han permitido mantener resultados a largo plazo, por esta razón los medicamentos contra la obesidad se vuelven una opción viable. Son cinco los medicamentos aprobados por la Dirección de Alimentos y Fármacos de Estados Unidos para el tratamiento a largo plazo de la obesidad: orlistat, fentarmina/topiramato de liberación prolongada, lorcarserina, naltrexona/ bupropión de liberación prolongada y liraglutida, mismos que han demostrado eficacia y seguridad necesaria para tomarse en cuenta como una opción terapéutica. En este artículo revisaremos la eficacia y seguridad de cada uno los medicamentos aprobados contra la obesidad que se encuentran disponibles.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Diagnóstico, Tratamiento y Prevención de Sobrepeso y Obesidad en el Adulto. México. Secretaría de Salud. Actualización 2012.

2. World Health Organization. Global status report on noncommunicable diseases 2014 [Internet]. apps.who.int. [cited 2015 Mar 1]. Disponible en: http://apps.who.int/iris/ bitstream/10665/148114/1/9789241564854_eng.pdf?ua

3. Johnson, N. B., Hayes, L. D., Brown, K., Hoo, E. C., Ethier, K. A., & the Centers for Disease Control and Prevention (CDC). CDC National Health Report: Leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005– 2013. MMWR Supplements 2014;63:3.27.

4. Bray G, Ryan D. Update on obesity pharmacotherapy. Ann NY Acad Sci 2014;131:1-13.

5. Hernández M. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016: Resultados ponderados. [Presentación] Instituto Nacional de Salud Pública. 14 de diciembre 2016.

6. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 Informe Final de Resultados.

7. Erlanger S, Henson E. Classification and Pharmacological Management of Obesity. P&T 2008;33(12):724-728.

8. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes 2005;29:1153-1167.

9. Moyer VA. Screening for and management of obesity in adults: U.S. preventive services task force recommendation. Ann Intern Med 2012;157:373-378.

10. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000;1:113-119.

11. Jensen M, Ryan D, Apovian C, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation 2014;129:S102-S138.

12. Pickett O, Newberry C. Future Therapies in Obesity. Gastroenterol Clin N Am 2016;45(4):705-714.

13. Suzuki K, Simpson K, Minnion J, et al. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J 2010;57(5):359-372.

14. MacDonald A, Billington C, Levine A. Alterations in food intake by opioid and dopamine signaling pathways between the ventral tegmental area and the shell of the nucleus accumbens. Brain Res 2004;1018(1):78-85.

15. Mietlicki-Baase E, Ortinski P, Rupprecht L, et al. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. Am J Physiol Endocrinol Metab 2013;305(11):E1367-E1374.

16. Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360(15):1518-1525.

17. Schulz TJ, Tseng Y-H. Systemic control of brown fat thermogenesis: integration of peripheral and central signals. Ann NY Acad Sci 2013;1302:35-41.

18. Jones B, Bloom S. The new era of drug therapy for obesity: The evidence and the expectations. Drugs 2005;75:935- 945.

19. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014;2(10):801-809.

20. Christensen R, Bartels E, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2007;66(4):433-439.

21. Connolly H, Crary J, McGoon M, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337(9):581-588.

22. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998;6(1):1-11.

23. James W, Caterson I, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363(10):905-917.

24. Sweeting A, Hocking S, Markovic T. Pharmacotherapy for the treatment of obesity. Molecular and Cellular Endocrinology 2015; doi: 10.1016/j.mce.2015.09.005.

25. Alamuddin N, Bakizada Z, Wadden T. Management of Obesity. J Clin Oncol 2016;34(35):4295-4305.

26. Yeh J. Obesity and Management of weight loss. N Engl J Med 2016;375;12:1187-1189.

27. Hurt R, Varayil J. New pharmacological treatments for the management of obesity. Curr Gastroenterol Rep 2014;16(394):1-8.

28. Togerson JS, Haupman J, Boldrin MN, et al. In the prevention of diabetes in obese subject (XENDOS) study; a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patient. Diabetes Care 2004;27(1):155-161.

29. O’Meara S, Riemsma R, Shirran L, et al. A systemic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004;5:51-68.

30. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009;11(4):361-371.

31. Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012;11(3):459-471.

32. Keith J. Pharmacotherapy in treatment of obesity. Gastroenterol Clin N Am 2016;45: 663-672.

33. Hanibuddin M, Humaira T. Pharmacological Management of obesity: Past, present and future. Saudi J Obesity 2014;2(1):3-12.

34. Kim G, Blomain E, Waldman S. Antiobesity pharmacotherapy: New drugs and emerging targets. Clin Pharmacol Ther 2014;95(1):53-66.

35. Smith S, Weissman N, Anderson C et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. New J Med 2010;363(3):245-256.

36. Fidles M, Sanchez M, Raether B et al. A one year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM Trial. J Clin Endocrinol Metab 2011;96:3067-3077.

37. O’Neil P, Smith S, Weissman N, et al. Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM- DM study. Obesity 2012;20(7):1426-1436.

38. Butsch S. Obesity medications: what does the future look like?. Curr Opin Endocrinol Diabetes Obes 2015;22(5):360- 366.

39. Umashanker D, Igel L, Kumar R, et al. Current and future medical treatment of obesity. Gastrointest Endoscopy Clin N Am 2017;27:181-190.

40. Gadde K. Current pharmacotherapy for obesity: extrapolation of clinical trials to practice. Expert Opin Pharmacother 2014;15(6):809-822.

41. Gadde K, Allison D, Ryan D, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebocontrolled, phase 3 trial. Lancet 2011;16(37):1341-1352.

42. Allison D, Gadde K, Garvey W, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012;20(2):330- 342.

43. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308.

44. Gadde K, Raj Y. Pharmacotherapy of obesity: Clinical trials to clinical practice. Curr Diab Rep 2017;17(34):1-9.

45. Bray G, Frühbeck G, Ryan D, et al. Management of obesity. Lancet 2016;387(10031):1974-1956.

46. Greenway FL, Fujioka K, Plodkowski R, et al., COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicenter, randomized double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376:595-605.

47. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/ bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011;19:110-120.

48. Apovian C, Aronne L, Rubino D, et al. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013;21:935-943.

49. Hollander P, Gupta A, Plodkowski R, et al. Effects of naltrexone sustained- release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:4022-4029.

50. Nissen S, Wolski K, Prcela L et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016;315(10):990-1004.

51. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2012;36:843- 854.

52. Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-caloriediet- induced weight loss: the SCALE Maintenance randomized study. Int J Obes 2013;37(11):1443-1251.

53. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373(1):11-22.

54. Lau D, Douketis J, Morrison K, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176(8):1-117.

55. The National Institute for Health and Care Excellence. Obesity: identification assessment and management (CG 189). NICE 2014.

56. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts 2015;8:402- 424.

57. AACE/ACE Guidelines American Association of Clinical Endocrinologists and American college of endocrinology. Clinical practice guidelines for comprehensive medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.

58. Guillemin M., Barnard E. (2015) George Libman Engel: The Biopsychosocial Model and the Construction of Medical Practice. In: Collyer F. (eds) The Palgrave Handbook of Social Theory in Health, Illness and Medicine. Palgrave Macmillan, London.

59. Kenneth E.F. Freedland Washington University School of Medicine. A new era for health psychology. Health Psychology 2017;36(1):1-4.